Interleukin Inhibitors Market - By Type (IL-1, IL-2, IL-5, IL-6, IL-17, & IL-23 Inhibitors), Route of Administration (Subcutaneous, Intravenous), Application (Rheumatoid Arthritis, Psoriasis, IBD, Asthma), End-user – Global Forecast 2024 – 2032

Interleukin Inhibitors Market Size

Interleukin Inhibitors Market size was valued at USD 24.3 billion in 2023 and is estimated to grow at 12% CAGR from 2024 to 2032. The market has seen considerable growth due to the rising prevalence of autoimmune and inflammatory diseases. Conditions are becoming increasingly common partly due to lifestyle changes, environmental factors, and improved diagnostic capabilities.
 

According to the National Stem Cell Foundation, nearly 4% of the world’s population is affected by one of more than 80 different autoimmune diseases. The most common of these diseases include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn’s disease, psoriasis, and scleroderma. Similarly, according to data reported by the National Psoriasis Foundation, around 125 million people worldwide (2 to 3 percent of the total population) have psoriasis.
 

This significant patient population tends to drive the demand for advanced treatment options which interleukin inhibitors provide by specifically targeting and modulating the immune system's inflammatory response thereby boosting market growth. Furthermore, advancements in biologic drugs, demand for personalized medicine, and growing awareness about early diagnosis and treatment significantly contribute to market expansion.
 

Interleukin inhibitors are a class of drugs that block the activity of specific interleukins, which are signaling proteins involved in regulating the immune system. These inhibitors work by interfering with the binding of interleukins to their receptors, thereby modulating the immune response and reducing inflammation.
 

Interleukin Inhibitors Market Trends

Increased investments in research and development (R&D) have resulted in the discovery of innovative therapies and advanced treatment options. These efforts have also propelled advancements in biologic therapy agents and precision medicine approaches, addressing the diverse needs of patients with interleukin inhibitors, thereby driving market expansion.
 

• For instance, in March 2024, Acelyrin, Inc. revealed promising outcomes from its global phase 2b/3 clinical trial of izokibep, a potential breakthrough in psoriatic arthritis treatment. Izokibep, a small protein therapeutic targeting IL-17A presented remarkable potency, strong tissue penetration capabilities, and an extended half-life. Thus, the availability of a strong product pipeline and associated treatment for broader applications will spur market growth.
   

Moreover, the increasing aging population with autoimmune diseases, advancements in diagnostic technologies, supportive government healthcare policies, and strategic expansions by major industry players further drives the market demand.
 

Interleukin Inhibitors Market Analysis

Based on the type, the market is categorized as IL-1 inhibitors, IL-2 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, IL-23 inhibitors, and other types. The IL-23 inhibitors segment is set to lead the market, accounting for the largest revenue of USD 6.5 billion, anticipating its dominance throughout the forecast period with a CAGR of 11.7%.
 

• The segmental growth is due to their high efficacy in treating chronic inflammatory and autoimmune conditions such as psoriasis and Crohn's disease. These inhibitors specifically target the IL-23 cytokine, which plays a crucial role in the inflammatory pathway, leading to significant clinical improvements and long-lasting remission in patients. Their targeted mechanism of action offers a favorable safety profile and fewer side effects compared to broader immunosuppressive therapies.
   
• For instance, in June 2024, Johnson & Johnson announced positive topline results from the pivotal Phase 3 GRAVITI study, investigating TREMFYA as a SC induction therapy for adults with moderately to severely active Crohn’s disease. TREMFYA is set to become the only IL-23 inhibitor to provide a complete SC therapy for both induction and maintenance of Crohn’s disease. These results highlighted its potential to offer a new, effective treatment option for patients.
   
• Thus, the introduction of innovative IL-23 inhibitors and strong clinical trial outcomes have further driven their adoption, making them a preferred treatment option in the market.

Based on route of administration, the interleukin inhibitors market is classified into subcutaneous (SC) and intravenous (IV). The subcutaneous segment holds the largest market share of 74.3% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• SC route dominance was asserted due to its convenience, ease of administration, and enhanced patient compliance. This route also typically involves fewer infusion-related reactions and provides more consistent drug absorption compared to IV administration.
   
• Further, the convenience and flexibility of SC administration are particularly beneficial for patients with chronic conditions, making it a preferred option for both patients and healthcare providers, thereby augmenting its market dominance.
   

Based on application, the interleukin inhibitors market is segmented into rheumatoid arthritis, psoriasis, inflammatory bowel disease (IBD), asthma, and other applications. The psoriasis segment is expected to lead the market projecting with a growth rate of 11.9% during the analysis period.
 

• The high segment growth is owing to the high prevalence and chronic nature of the disease, which requires ongoing and effective management. Interleukin inhibitors, particularly those targeting IL-17 and IL-23, have shown significant efficacy in reducing the symptoms and progression of psoriasis, leading to their widespread adoption.
   
• For instance, in May 2024, Zai Lab Limited announced the dosing of the first patient in a global Phase 2 trial (NCT06380907) for its anti-IL-17 therapy, ZL-1102, targeting chronic plaque psoriasis (CPP). ZL-1102, a novel human VH antibody fragment, is being developed as a topical treatment for mild-to-moderate CPP, unlike other systemic anti-IL-17 products. This innovative approach aimed to offer a convenient and targeted treatment option for patients with mild-to-moderate CPP, potentially revolutionizing the management of the disease.
   
• Therefore, the presence of substantial clinical data confirming the long-term efficacy and safety of these therapies has strengthened their widespread adoption.
   

Based on the end-user, the interleukin inhibitors market is segmented into hospitals, specialty clinics, and research and academic institutes. The hospital segment dominated the market with the highest share in 2023.
 

• Hospitals have dominated the market due to their role as primary centers for administering these treatments, which often require medical supervision and specialized equipment.
   
• Hospitals are equipped to manage potential side effects and provide comprehensive care, making them preferred settings for initiating and monitoring interleukin inhibitor therapies. Additionally, the complexity and cost of these biologic treatments typically necessitate hospital-based administration, especially for intravenous formulations.
   
• Thus, the dominance is supported by aforementioned factor along with hospital's ability to conduct necessary diagnostic tests, track patient progress, and ensure adherence to treatment protocols, thereby optimizing therapeutic outcomes.

The U.S. dominated the North American interleukin inhibitors market accounting for USD 9.3 billion in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The U.S. prominence was asserted due to the widespread access to innovative treatments, and a large patient population. For instance, according to the National Psoriasis Foundation, approximately 2.4 million individuals in the U.S. are affected by psoriatic arthritis. Similarly, an estimated 15% of individuals with psoriasis may be undiagnosed with psoriatic arthritis. This high prevalence underscored the significant demand for effective treatment options, thereby driving the expansion of the market for interleukin inhibitors in the U.S. market.
   
• Additionally, the presence of key pharmaceutical companies and research institutions coupled with supportive government policies as well as insurance coverage contribute to the market's growth.
   

Germany exhibited a high growth potential in the European interleukin inhibitors market.
 

• Germany's prominence was asserted due to its advanced healthcare infrastructure, substantial investment in biomedical research, and high prevalence of autoimmune and inflammatory diseases. Also, Germany's regulatory environment is conducive to the swift approval and adoption of new biologic treatments, further driving the demand for interleukin inhibitors.
   
• Moreover, the aging population that is more prone to these diseases further boosts market growth by increasing the demand for effective treatments. For instance, as per the October 2021 update from the World Health Organization, the population of individuals aged over 60 is projected to rise from 12% in 2015 to 22% by 2050. This growing geriatric population is likely to place increased demand on healthcare systems, thereby driving the growth of the market over the forecast period.
   

The Asia Pacific interleukin inhibitors market is poised for rapid growth with a CAGR of 12.4% during the forecast period.
 

• The Asia Pacific market is poised for rapid growth due to several factors such as the region's expanding population, product approvals coupled with increasing awareness and diagnosis rates of autoimmune disease.
   
• For instance, in August 2021, Novartis received the China National Medical Products Administration (NMPA) approval for Cosentyx to treat moderate-to-severe plaque psoriasis in pediatric patients (six years and older with a body weight ≥50 kg) who are candidates for systemic therapy or phototherapy. The drug was already approved in China for treating moderate-to-severe plaque psoriasis in adults and adult ankylosing spondylitis. This approval marked a significant expansion of treatment options for pediatric patients with plaque psoriasis in China.
   
• Thus, the introduction of innovative treatment options and strategic investments by pharmaceutical companies in the region are expected to fuel the regional market growth.
   

Interleukin Inhibitors Market Share

The interleukin inhibitors industry is characterized by intense competition, with companies focusing on extensive R&D investments, strong product portfolios, and strategic collaborations. New entrants and smaller biopharmaceutical companies are also contributing to the market dynamics with innovative therapies and niche applications. Also, continuous advancements in biologic treatments and precision medicine, along with robust clinical pipelines, drive competition. Additionally, the expanding indications for interleukin inhibitors and increasing approvals by regulatory authorities further intensify the competitive landscape.
 

Interleukin Inhibitors Market Companies

Few of the prominent players operating in the interleukin inhibitors industry include:

• AbbVie Inc.
• Biogen
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• Genentech USA, Inc. 
• Janssen Pharmaceutical Companies (Johnson and Johnson)
• Novartis AG
• Regeneron Pharmaceuticals, Inc. 
• Samsungbioepis Co,.Ltd.
• Sanofi
• Sobi, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• UCB S.A
   

Interleukin Inhibitors Industry News:

• In April 2024, Alvotech and Teva Pharmaceuticals' biosimilar, Selarsdi (blocking the activity of IL-12 and IL-23), gained FDA approval as an alternative to Stelara. Indicated for patients aged 6 and above with moderate to severe plaque psoriasis and active psoriatic arthritis. This approval is expected to expand their outreach to untapped economies.
   
• In October 2023, Eli Lilly and Company received U.S. Food and Drug Administration (FDA) approval for Omvo infusion, marking it as the first and only interleukin-23p19 (IL-23p19) antagonist for treating moderately to severely active ulcerative colitis (UC) in adults. This approval strategy is expected to enhance their product offerings.
   

The interleukin inhibitors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• IL-1 inhibitors
• IL-2 inhibitors
• IL-5 inhibitors
• IL-6 inhibitors
• IL-17 inhibitors
• IL-23 inhibitors
• Other types

Market, By Route of Administration

• Subcutaneous (SC)
• Intravenous (IV)

Market, By Application

• Rheumatoid arthritis
• Psoriasis
• Inflammatory bowel disease (IBD)
• Asthma
• Other applications

Market, By End-user

• Hospital
• Specialty clinics
• Research and academic institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa